NO133802B - - Google Patents
Download PDFInfo
- Publication number
- NO133802B NO133802B NO343/71*[A NO34371A NO133802B NO 133802 B NO133802 B NO 133802B NO 34371 A NO34371 A NO 34371A NO 133802 B NO133802 B NO 133802B
- Authority
- NO
- Norway
- Prior art keywords
- vitamin
- acid
- group
- approx
- general formula
- Prior art date
Links
- 229930002330 retinoic acid Natural products 0.000 claims description 27
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- -1 n-decyl Chemical group 0.000 description 6
- 206010020915 Hypervitaminosis Diseases 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000006122 hypervitaminosis A Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- WKYDOCGICAMTKE-NBIQJRODSA-N n-ethyl retinamide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C WKYDOCGICAMTKE-NBIQJRODSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- AZJQQNWSSLCLJN-UHFFFAOYSA-N 2-ethoxyquinoline Chemical compound C1=CC=CC2=NC(OCC)=CC=C21 AZJQQNWSSLCLJN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH142870A CH529742A (de) | 1970-02-02 | 1970-02-02 | Verfahren zur Herstellung von Vitamin-A-Säureamiden |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO133802B true NO133802B (ja) | 1976-03-22 |
| NO133802C NO133802C (ja) | 1976-06-30 |
Family
ID=4210229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO343/71*[A NO133802C (ja) | 1970-02-02 | 1971-02-01 |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS544948B1 (ja) |
| AT (1) | AT303274B (ja) |
| BE (1) | BE762345A (ja) |
| CA (1) | CA963910A (ja) |
| CH (1) | CH529742A (ja) |
| DE (1) | DE2102586C2 (ja) |
| DK (1) | DK136311B (ja) |
| ES (1) | ES387834A1 (ja) |
| FI (1) | FI52715C (ja) |
| FR (1) | FR2081477B1 (ja) |
| GB (1) | GB1283887A (ja) |
| IE (1) | IE35133B1 (ja) |
| IL (1) | IL35987A (ja) |
| NL (1) | NL168415C (ja) |
| NO (1) | NO133802C (ja) |
| SE (1) | SE373133B (ja) |
| YU (1) | YU34355B (ja) |
| ZA (1) | ZA71142B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2300107C2 (de) * | 1973-01-03 | 1982-03-11 | Basf Ag, 6700 Ludwigshafen | Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen |
| US4310546A (en) * | 1978-07-31 | 1982-01-12 | Johnson & Johnson | Novel retinoids and their use in preventing carcinogenesis |
| DE2843915A1 (de) * | 1978-10-07 | 1980-04-24 | Basf Ag | N-benzoyl-retinylamine |
| DE2843870A1 (de) * | 1978-10-07 | 1980-04-24 | Basf Ag | N-hydroxypropylamide der all-e- und 13-z-retinsaeure |
| DE3002545A1 (de) * | 1980-01-25 | 1981-07-30 | Basf Ag, 6700 Ludwigshafen | 5-amino-tetrazol-derivate von retinsaeuren, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| CH651007A5 (de) * | 1982-06-24 | 1985-08-30 | Hoffmann La Roche | Polyenverbindungen. |
| WO1997009307A1 (en) * | 1995-09-01 | 1997-03-13 | Gist-Brocades B.V. | Retinoylamide based derivatives of sphingoid bases |
| US7566808B2 (en) * | 2004-02-17 | 2009-07-28 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| WO2006005455A2 (en) * | 2004-07-09 | 2006-01-19 | Dsm Ip Assets B.V. | Amino, amino acid or peptide conjugates of retinoic acid |
| KR100837186B1 (ko) * | 2006-09-29 | 2008-06-13 | (주)아모레퍼시픽 | 항노화 효과를 나타내는 레티노익산 유도체 및 이의제조방법 |
| US11148998B2 (en) | 2017-05-23 | 2021-10-19 | The Regents Of The University Of Michigan | Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH195065A (de) * | 1936-11-23 | 1938-01-15 | Int Suiker En Alcohol Compagni | Einrichtung an Vacuumapparaten zum Erleichtern des Auswechselns einzelner Röhren. |
| NL257621A (ja) * | 1959-11-23 | |||
| FR1297730A (fr) * | 1960-11-04 | 1962-07-06 | Hoffmann La Roche | Préparation cosmétique |
| FR1320153A (fr) * | 1962-01-22 | 1963-03-08 | Sumitomo Chemical Co | Procédé de production de composés dérivés de l'acide de vitamine a 2-trans |
-
1970
- 1970-02-02 CH CH142870A patent/CH529742A/de not_active IP Right Cessation
- 1970-12-09 FI FI703317A patent/FI52715C/fi active
- 1970-12-15 NL NLAANVRAGE7018260,A patent/NL168415C/xx not_active IP Right Cessation
- 1970-12-28 YU YU3184/70A patent/YU34355B/xx unknown
-
1971
- 1971-01-11 ZA ZA710142A patent/ZA71142B/xx unknown
- 1971-01-12 IL IL35987A patent/IL35987A/xx unknown
- 1971-01-20 DE DE2102586A patent/DE2102586C2/de not_active Expired
- 1971-01-29 FR FR7103020A patent/FR2081477B1/fr not_active Expired
- 1971-01-29 CA CA103,975A patent/CA963910A/en not_active Expired
- 1971-01-29 DK DK40571AA patent/DK136311B/da not_active Application Discontinuation
- 1971-02-01 ES ES387834A patent/ES387834A1/es not_active Expired
- 1971-02-01 NO NO343/71*[A patent/NO133802C/no unknown
- 1971-02-01 JP JP356271A patent/JPS544948B1/ja active Pending
- 1971-02-01 AT AT79971A patent/AT303274B/de not_active IP Right Cessation
- 1971-02-01 BE BE762345A patent/BE762345A/xx not_active IP Right Cessation
- 1971-02-02 SE SE7101274A patent/SE373133B/xx unknown
- 1971-02-02 IE IE118/71A patent/IE35133B1/xx unknown
- 1971-04-19 GB GB20880/71A patent/GB1283887A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2081477A1 (ja) | 1971-12-03 |
| FR2081477B1 (ja) | 1974-03-22 |
| FI52715B (ja) | 1977-08-01 |
| YU34355B (en) | 1979-07-10 |
| ES387834A1 (es) | 1973-06-01 |
| DK136311B (da) | 1977-09-26 |
| DE2102586C2 (de) | 1985-03-14 |
| NL168415B (nl) | 1981-11-16 |
| IL35987A0 (en) | 1971-03-24 |
| IL35987A (en) | 1974-01-14 |
| FI52715C (fi) | 1977-11-10 |
| JPS544948B1 (ja) | 1979-03-12 |
| IE35133L (en) | 1971-08-02 |
| CH529742A (de) | 1972-10-31 |
| NL7018260A (ja) | 1971-08-04 |
| AT303274B (de) | 1972-11-27 |
| DE2102586A1 (de) | 1971-08-12 |
| IE35133B1 (en) | 1975-11-26 |
| SE373133B (ja) | 1975-01-27 |
| GB1283887A (en) | 1972-08-02 |
| DK136311C (ja) | 1978-02-20 |
| BE762345A (fr) | 1971-08-02 |
| ZA71142B (en) | 1971-10-27 |
| NL168415C (nl) | 1982-04-16 |
| YU318470A (en) | 1978-12-31 |
| NO133802C (ja) | 1976-06-30 |
| CA963910A (en) | 1975-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jenkins et al. | Inhibition of adrenal steroid 11-oxygenation in the dog | |
| CA1142092A (en) | Method of preventing carcinogenesis | |
| AU2011344030B2 (en) | 3-methanesulfonylpropionitrile for treating inflammation and pain | |
| EP1736167B1 (en) | Extracts obtained from cell line cultures from Syringa vulgaris IRB-SV25/B (DMS:16857), their preparation and use | |
| JPH03170499A (ja) | ドラスタチン１４ | |
| NO133802B (ja) | ||
| AU688029B2 (en) | An equilin double bond isomer from the acid isomerization of equilin | |
| JPS61260091A (ja) | 新規なエリスロマイシンａ・脂肪酸エステル、それらの製法及びそれらを含有している医薬及び化粧料組成物 | |
| NO149999B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme n-(4-acyloksyfenyl)-all-trans-retinamider | |
| Thompson et al. | Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans-retinamide in rats and mice | |
| Hirschberg et al. | Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl) aminomethyl] benzimidazole, and of other 2-chloroethyl compounds | |
| KR0169536B1 (ko) | 신규한 인삼 사포닌, 그의 제조방법 및 이를 유효성분으로 하는 항종양제 | |
| JPS6236395A (ja) | プソイドプテロシンの合成誘導体、及びそれを含む剤 | |
| US5061723A (en) | Non-teratogenic vitamin A preparation for women of child-bearing age | |
| US3170923A (en) | 17-tetrahydropyranylethers of delta4, 6-androstadienes | |
| EP0038567B1 (en) | Deazapurine nucleoside, formulations thereof, and use thereof in therapy | |
| JPH07179418A (ja) | ビタミンｄ３−類似体 | |
| CN111393451B (zh) | 一种基于黄柏酮的化合物 | |
| EP0983063B1 (en) | Pharmaceutical composition containing uscharin | |
| Farnsworth et al. | Medicinal plants in therapy | |
| EP0194710A2 (en) | New derivative of fructose, its preparation and its uses | |
| US3574853A (en) | Composition and method of reducing serum cholesterol with thiobiscresols | |
| KR0143719B1 (ko) | 백하수오로부터 추출한 암세포의 다중약제내성조절 작용을 갖는 폴리옥시프레그난 배당체 | |
| JP2554248B2 (ja) | 新規４−メトキシ−２，３，６−トリメチルベンゼン−１−置換誘導体、その製法およびそれを含む医薬または化粧組成物 | |
| JP2003055369A (ja) | 新規なフロログルシノール誘導体、及びこれを用いた組成物、抗アレルギー剤 |